Table 6.
Hormone receptor status | Subset of immune cells | Pure DCIS (n = 231) | DCIS-M (n = 81) | DCIS-INV (n = 90) | p value | |||
---|---|---|---|---|---|---|---|---|
Three groups* | Pure DCIS vs. DCIS-M# | Pure DCIS vs. DCIS-INV# | DCIS-M vs. DCIS-INV# | |||||
All (n = 402) | CD4+ TIL | 19.3 (4.0–47.8) | 46.3 (16.7–112.1) | 38.5 (12.0–101.8) | < 0.001 | < 0.001 | < 0.001 | 1.000 |
CD8+ TIL | 12.3 (5.3–25.0) | 18.7 (6.3–47.8) | 18.0 (5.5–44.3) | 0.027 | 0.057 | 0.168 | 1.000 | |
FOXP3+ TIL | 0 (0–1.0) | 1.5 (0.0–10.0) | 1.0 (0.0–3.3) | < 0.001 | < 0.001 | < 0.001 | 1.000 | |
PD-L1+ IC | 34/221 (15.4) | 20/78 (25.6) | 19/90 (21.1) | 0.111 | 0.129 | 0.669 | 1.000 | |
Positive (n = 311) | CD4+ TIL | 17.0 (3.7–43.3) | 18.3 (6.7–85.7) | 18.0 (10.0–65.0) | 0.040 | 0.606 | 0.051 | 1.000 |
CD8+ TIL | 11.7 (5.3–22.0) | 15.3 (5.2–34.7) | 11.0 (3.0–33.0) | 0.684 | 1.000 | 1.000 | 1.000 | |
FOXP3+ TIL | 0.0 (0.0–0.0) | 0.0 (0.0–2.0) | 1.0 (0.1–2.0) | < 0.001 | 0.225 | < 0.001 | 0.573 | |
PD-L1+ IC | 26/196 (13.3) | 6/38 (15.8) | 9/67 (13.4) | 0.916 | 1.000 | 1.000 | 1.000 | |
Negative (n = 91) | CD4+ TIL | 35.0 (18.0–86.5) | 63.3 (31.7–115.0) | 101.0 (53.0–185.0) | 0.001 | 0.036 | 0.003 | 0.063 |
CD8+ TIL | 22.7 (9.2–48.8) | 25.7 (9.0–64.0) | 45.0 (23.0–81.0) | 0.007 | 1.000 | 0.009 | 0.027 | |
FOXP3+ TIL | 1.0 (0.0–5.0) | 4.0 (1.0–12.0) | 4.0 (1.0–6.0) | 0.076 | 0.114 | 0.159 | 1.000 | |
PD-L1+ IC | 8/25 (32.0) | 14/40 (35.0) | 10/23 (43.5) | 0.690 | 1.000 | 1.000 | 1.000 |
*For the comparison of three groups, the Kruskal-Wallis test or chi-square test was used
#For the comparison of two groups, the Mann-Whitney U test or chi-square test was used. Corrections for multiple testing are performed with the Bonferroni method, and adjusted (adj.) p values are presented
Data are presented as median (interquartile range) for CD4+, CD8+, and FOXP3+ TILs and as frequency (%) for PD-L1+ IC
TIL tumor-infiltrating lymphocyte, IC immune cell, DCIS ductal carcinoma in situ, DCIS-M DCIS with microinvasion, DCIS-INV DCIS associated with invasive carcinoma